| 甄胜达,张娜,张晓强,张立国,乔鑫,张成军,乔福斌.依洛尤单抗对PCI 术后血脂未达标的高脂血症冠心病患者脂代谢的影响.[J].中南医学科学杂志.,2024,(5):843-845, 860. |
| 依洛尤单抗对PCI 术后血脂未达标的高脂血症冠心病患者脂代谢的影响 |
| The effects of Elomumab on lipid metabolism in patients with hyperlipidemia and coronary heart disease who did not meet the standard of blood lipids after PCI |
| 投稿时间：2024-04-10 修订日期：2024-07-18 |
| DOI：10.15972/j.cnki.43-1509/r.2024.05.038 |
| 中文关键词: 冠心病 高血脂症 依洛尤单抗 经皮冠状动脉介入 脂代谢 临床终点事件 |
| 英文关键词:coronary heart disease hyperlipemia evolocumab percutaneous coronary intervention lipid metabolism clinical endpoint event |
| 基金项目:邢台市重点研发计划项目(2022ZC24) |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的探讨依洛尤单抗对经皮冠状动脉介入(PCI)术后血脂未达标的高脂血症冠心病患者脂代谢的影响。 方法将72例经PCI术后血脂未达标的高脂血症冠心病患者随机均分为对照组(基础他汀类药物治疗)及观察组(基础他汀类药物联合依洛尤单抗治疗)。比较两组治疗效果、治疗前后脂代谢指标、临床终点事件和安全性。 结果观察组总有效率高于对照组(P＜0.05);两组治疗3个月后,高密度脂蛋白胆固醇高于治疗前,且观察组高于对照组(P＜0.05);甘油三酯、低密度脂蛋白胆固醇、总胆固醇低于治疗前,且观察组低于对照组(P＜0.05);观察组不稳定型心绞痛再住院率、心肌梗死发生率低于对照组(P＜0.05)。两组不良反应发生率比较无统计学意义(P＞0.05)。 结论依洛尤单抗能改善PCI术后血脂未达标的高脂血症冠心病患者脂代谢,降低不稳定型心绞痛再住院及心肌梗死风险,疗效确切,且不增加不良反应。 |
| 英文摘要: |
| AimTo investigate the effects of Elomumab on lipid metabolism in patients with hyperlipidemia and coronary heart disease who have not yet reached blood lipid levels after percutaneous coronary intervention (PCI). Methods72 patients with hyperlipidemia and coronary heart disease who did not achieve blood lipid levels after PCI were randomly divided into a control group (treated with basic statins) and an observation group (treated with basic statins combined with erlotinib). The treatment efficacy, lipid metabolism indicators before and after treatment, clinical endpoint events, and safety between two groups, were compared. ResultsThe total effective rate of the observation group was higher than that of the control group (P＜0.05); After 3 months of treatment in both groups, high-density lipoprotein cholesterol levels were higher than those before treatment, and the observation group was higher than the control group (P＜0.05); Triglycerides, low-density lipoprotein cholesterol, and total cholesterol were lower than those before treatment, and the observation group was lower than the control group (P＜0.05); The readmission rate and incidence of myocardial infarction in the observation group with unstable angina pectoris were lower than those in the control group (P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionElomumab can improve lipid metabolism and reduce the risk of readmission and myocardial infarction in patients with hyperlipidemia and coronary heart disease who did not meet blood lipid standards after PCI. The efficacy is definite and does not increase adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|